Retatrutide Advances Through Phase 3 Trials: What the Latest Research Actually Shows
Published Aug 18, 2026
5 min read
Retatrutide has quickly become one of the most closely watched investigational peptides in obesity research.
And the latest clinical-trial results have given researchers — and the pharmaceutical industry — plenty to talk about.
In July, Eli Lilly announced positive topline results from two additional Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, adding to an expanding body of clinical data surrounding the investigational drug.
Important distinction: Retatrutide is still investigational. It has not been approved by the FDA or another regulatory agency.
So what have researchers actually learned so far?
What Is Retatrutide?
Retatrutide, also known as LY3437943, is a once-weekly investigational peptide designed to activate three hormone receptors: GIP, GLP-1, and glucagon.
That three-pathway approach is what makes retatrutide different from currently approved medications that target fewer pathways. Researchers are studying whether this combination can produce meaningful effects on body weight, blood glucose, and other metabolic outcomes.
The Latest Phase 3 Results
In July 2026, Lilly reported results from two major Phase 3 studies.
TRIUMPH-2
TRIUMPH-2 studied adults with obesity or overweight who also had type 2 diabetes. At 80 weeks, Lilly reported average weight reductions of:
Retatrutide dose Average weight reduction
4 mg 12.7%
9 mg 19.1%
12 mg 20.8%
Placebo 4.0%
The 12 mg group experienced an average reduction of approximately 49.6 pounds from a baseline average weight of about 234.6 pounds. The study also reported reductions in HbA1c, with reductions of up to an average of 1.6 percentage points depending on dose.
TRIUMPH-3
TRIUMPH-3 looked at adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Lilly reported that participants receiving the highest studied dose lost an average of approximately 22.6% of body weight at 80 weeks, or about 55.8 pounds.
These results add to earlier Phase 3 findings from TRIUMPH-1. In that study, participants receiving 12 mg of retatrutide lost an average of 28.3% of body weight over 80 weeks.
Why Researchers Are Paying Attention
The results are notable because retatrutide is attempting something different from traditional single-pathway approaches. Instead of targeting GLP-1 alone, retatrutide activates three related biological pathways.
That raises an interesting research question: can simultaneously targeting GIP, GLP-1 and glucagon produce greater metabolic effects than targeting fewer pathways?
The Phase 3 results so far suggest that the drug has substantial activity — but researchers still need to evaluate the complete safety and efficacy picture. And that’s where clinical trials become particularly important.
What Phase 3 Actually Means
Seeing the words “Phase 3” can sound like a drug is almost approved. That’s not necessarily the case. Drug development generally progresses through several stages:
Phase 1: Usually focuses heavily on safety, tolerability, and how the drug behaves in the body.
Phase 2: Looks more closely at efficacy, dose selection, and continued safety.
Phase 3: Large studies designed to provide substantial evidence about effectiveness and safety in the intended patient population.
Even successful Phase 3 trials don’t automatically equal FDA approval. The FDA must still review the complete application and determine whether the benefits outweigh the risks for the proposed use.
What Happens Next?
Lilly has said it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. That means the next major chapter in the retatrutide story will be regulatory review.
Additional clinical data will also continue to emerge from the broader development program. For example, ClinicalTrials.gov currently lists additional Phase 3 studies examining retatrutide in areas including weight maintenance and type 2 diabetes.
The Part That’s Easy to Miss
The headlines surrounding retatrutide can make it sound like the research is finished. It isn’t.
Positive topline results are encouraging, but they aren’t the same as a completed regulatory evaluation. The detailed trial results still matter. Researchers and regulators will want to examine questions involving:
Adverse events
Treatment discontinuations
Long-term safety
Different patient populations
Cardiovascular outcomes
Glycemic effects
Dose-response relationships
How benefits compare with existing treatments
Lilly has said detailed results from TRIUMPH-2 and TRIUMPH-3 will be presented at future medical meetings and published in peer-reviewed journals. That distinction is important for anyone following peptide research.
What About the Retatrutide Being Sold Online?
This is where the research story intersects with a very different issue.
Because retatrutide remains investigational, products being sold outside legitimate clinical research should not be confused with the drug being studied in Lilly’s clinical trials.
Lilly specifically warns that retatrutide has not been approved by any regulatory agency and advises against taking products claiming to be retatrutide outside a Lilly-sponsored clinical trial.
In other words: clinical-trial retatrutide is not the same as an online product labeled “retatrutide.” The identity, purity, concentration, and manufacturing controls of an unauthorized product cannot simply be assumed from the label.
The Vile Peptide Talk Takeaway
Retatrutide is one of the most interesting peptide stories in the current clinical-development pipeline. The Phase 3 results released so far are substantial and help explain why researchers and pharmaceutical companies are watching the molecule closely.
But the most responsible way to interpret the news is to keep three things separate: promising clinical data doesn’t automatically mean FDA approval, and FDA approval doesn’t automatically mean every product sold under the same name is equivalent.
The next major milestone will be Lilly’s planned FDA submission in 2027. Until then, retatrutide remains an investigational peptide, and the research — not the hype — is what deserves the attention.
Sources
Eli Lilly — Phase 3 TRIUMPH-2 and TRIUMPH-3 results
ClinicalTrials.gov — Retatrutide clinical-trial records
Eli Lilly — Retatrutide research and regulatory status
Research disclaimer: This article is for educational and informational purposes only. Retatrutide is an investigational drug and has not been approved by the FDA. Nothing in this article is intended as medical advice, a treatment recommendation, or an endorsement of using investigational or unapproved products.